Shanghai Shen Lian Biomedical Corporation Class ASSE: 688098

"Shanghai Shen Lian Biomedical Corporation"Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

Sep 8, 2026 · Issued by Shanghai Shen Lian Biomedical Corporation Class A via Shanghai Stock Exchange

Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Shanghai Shen Lian Biomedical Corporation Class A

"Shanghai Shen Lian Biomedical Corporation"Announcement on Appointment of Deputy General ManagerAug 31
"Shanghai Shen Lian Biomedical Corporation"Announcement on Voluntary Disclosure of Approval of the Veterinary Drug Product Approval Number for the Bivalent Synthetic Peptide Vaccine against Swine Foot-and-Mouth Disease Types O and SAT1Aug 26
"Shanghai Shen Lian Biomedical Corporation"Announcement on Voluntary Disclosure of Obtaining the Approval for Veterinary Drug Product Approval NumberJul 22
"Shanghai Shen Lian Biomedical Corporation"Announcement on Voluntary Disclosure of Approval of Veterinary Drugs Containing SAT 1 Foot-and-Mouth Disease VaccineJul 21

All Shanghai Shen Lian Biomedical Corporation Class A news releases